Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 9
Submit an article Journal homepage
483
Views
83
CrossRef citations to date
0
Altmetric
Review

The role of cathelicidin and defensins in pulmonary inflammatory diseases

Christian Herr Philipps-University, Department of Internal Medicine, Division for Pulmonary Diseases, Marburg, Germany +49 0 6421 286 4994; +49 0 6421 28 68987; [email protected]
,
Renat Shaykhiev Philipps-University, Department of Internal Medicine, Division for Pulmonary Diseases, Marburg, Germany +49 0 6421 286 4994; +49 0 6421 28 68987; [email protected]
&
Robert Bals
Pages 1449-1461 | Published online: 29 Aug 2007

Bibliography

  • WHITSETT JA: Intrinsic and innate defenses in the lung: intersection of pathways regulating lung morphogenesis, host defense, and repair. J. Clin. Invest. (2002) 109:565-569.
  • BALS R, HIEMSTRA PS: Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur. Respir. J. (2004) 23:327-333.
  • BINGLE CD, CRAVEN CJ: PLUNC: a novel family of candidate host defence proteins expressed in the upper airways and nasopharynx. Hum. Mol. Genet. (2002) 11:937-943.
  • ZANETTI M, GENNARO R, ROMEO D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. (1995) 374:1-5.
  • BOMAN HG: Gene-encoded peptide antibiotics and the concept of innate immunity: an update review. Scand. J. Immunol. (1998) 48:15-25.
  • LEHRER RI, GANZ T: Antimicrobial peptides in mammalian and insect host defence. Curr. Opin. Immunol. (1999) 11:23-27.
  • GANZ T, LEHRER RI: Antimicrobial peptides of vertebrates. Curr. Opin. Immunol. (1998) 10:41-44.
  • RAMANATHAN B, DAVIS EG, ROSS CR, BLECHA F: Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes. Infect. (2002) 4:361-372.
  • GUDMUNDSSON GH, AGERBERTH B, ODEBERG J, BERGMAN T, OLSSON B, SALCEDO R: The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. (1996) 238:325-332.
  • FROHM NM, SANDSTEDT B, SORENSEN O, WEBER G, BORREGAARD N, STAHLE-BACKDAHL M: The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect. Immun. (1999) 67:2561-2566.
  • HIRATA M, SHIMOMURA Y, YOSHIDA M et al.: Characterization of a rabbit cationic protein (CAP18) with lipopolysaccharide-inhibitory activity. Infect. Immun. (1994) 62:1421-1426.
  • AUMELAS A, MANGONI M, ROUMESTAND C et al.: Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur. J. Biochem. (1996) 237:575-583.
  • FAHRNER RL, DIECKMANN T, HARWIG SS, LEHRER RI, EISENBERG D, FEIGON J: Solution structure of protegrin-1, a broad spectrum antimicrobial peptide from porcine leukocytes. Chem. Biol. (1996) 3:543-550.
  • COWLAND JB, JOHNSEN AH, BORREGAARD N: hCAP-18, a cathelin/pro-bactenecin-like protein of human neutrophil specific granules. FEBS Lett. (1995) 368:173-176.
  • BALS R, WANG X, ZASLOFF M, WILSON JM: The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl. Acad. Sci. USA (1998) 95:9541-9546.
  • AGERBERTH B, CHARO J, WERR J et al.: The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood (2000) 96:3086-3093.
  • AGERBERTH B, GRUNEWALD J, CASTANOS-VELEZ E et al.: Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am. J. Respir. Crit. Care Med. (1999) 160:283-290.
  • SORENSEN OE, FOLLIN P, JOHNSEN AH et al.: Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with protease 3. Blood (2001) 97:3951-3959.
  • SORENSEN OE, GRAM L, JOHNSEN AH et al.: Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J. Biol. Chem. (2003) 278:28540-28546.
  • MURAKAMI M, LOPEZ-GARCIA B, BRAFF M, DORSCHNER RA, GALLO RL: Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J. Immunol. (2004) 172:3070-3077.
  • YAMASAKI K, SCHAUBER J, CODA A et al.: Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. (2006) 20:2068-2080.
  • ZAIOU M, NIZET V, GALLO RL: Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J. Invest. Dermatol. (2003) 120:810-816.
  • GANZ T, LEHRER RI: Defensins. Pharmacol. Ther. (1995) 66:191-205.
  • GANZ T, SELSTED ME, SZKLAREK D et al.: Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest. (1985) 76:1427-1435.
  • WILDE CG, GRIFFITH JE, MARRA MN, SNABLE JL, SCOTT RW: Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J. Biol. Chem. (1989) 264:11200-11203.
  • JONES DE, BEVINS CL: Paneth cells of the human small intestine express an antimicrobial peptide gene. J. Biol. Chem. (1992) 267:23216-23225.
  • JONES DE, BEVINS CL: Defensin-6 mRNA in human Paneth cells: implications for antimicrobial peptides in host defense of the human bowel. FEBS Lett. (1993) 315:187-192.
  • BENSCH KW, RAIDA M, MAGERT HJ, SCHULZ-KNAPPE P, FORSSMANN WG: hBD-1: a novel β-defensin from human plasma. FEBS Lett. (1995) 368:331-335.
  • MCCRAY PB Jr, BENTLEY L: Human airway epithelia express a β-defensin. Am. J. Respir. Cell Mol. Biol. (1997) 16:343-349.
  • GOLDMAN MJ, ANDERSON GM, STOLZENBERG ED, KARI UP, ZASLOFF M, WILSON JM: Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 88:553-560.
  • VALORE EV, PARK CH, QUAYLE AJ, WILES KR, MCCRAY PB, GANZ T Jr: Human β-defensin-1: an antimicrobial peptide of urogenital tissues. J. Clin. Invest. (1998) 101:1633-1642.
  • HARDER J, BARTELS J, CHRISTOPHERS E, SCHRODER JM: A peptide antibiotic from human skin. Nature (1997) 387:861.
  • BALS R, WANG X, WU Z et al.: Human β-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J. Clin. Invest. (1998) 102:874-880.
  • SINGH PK, JIA HP, WILES K et al.: Production of β-defensins by human airway epithelia. Proc. Natl. Acad. Sci. USA (1998) 95:14961-14966.
  • DUITS LA, RAVENSBERGEN B, RADEMAKER M, HIEMSTRA PS, NIBBERING PH: Expression of β-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology (2002) 106:517-525.
  • JIA HP, SCHUTTE BC, SCHUDY A et al.: Discovery of new human β-defensins using a genomics-based approach. Gene (2001) 263:211-218.
  • HARDER J, BARTELS J, CHRISTOPHERS E, SCHRODER JM: Isolation and characterization of human β -defensin-3, a novel human inducible peptide antibiotic. J. Biol. Chem. (2001) 276:5707-5713.
  • GARCIA JR, JAUMANN F, SCHULZ S et al.: Identification of a novel, multifunctional β-defensin (human β-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. (2001) 306:257-264.
  • GARCIA JR, KRAUSE A, SCHULZ S et al.: Human β-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. (2001) 15:1819-1821.
  • ARMOGIDA SA, YANNARAS NM, MELTON AL, SRIVASTAVA MD: Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc. (2004) 25:297-304.
  • ISHIMOTO H, MUKAE H, DATE Y et al.: Identification of hBD-3 in respiratory tract and serum: the increase in pneumonia. Eur. Respir. J. (2006) 27:253-260.
  • YANAGI S, ASHITANI J, ISHIMOTO H et al.: Isolation of human β-defensin-4 in lung tissue and its increase in lower respiratory tract infection. Respir. Res. (2005) 6:130.
  • SCHUTTE BC, MITROS JP, BARTLETT JA et al.: Discovery of five conserved β-defensin gene clusters using a computational search strategy. Proc. Natl. Acad. Sci. USA (2002) 99:2129-2133.
  • TANG YQ, YUAN J, OSAPAY G et al.: A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated α-defensins. Science (1999) 286:498-502.
  • TRAN D, TRAN PA, TANG YQ, YUAN J, COLE T, SELSTED ME: Homodimeric θ-defensins from rhesus macaque leukocytes: isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic peptides. J. Biol. Chem. (2002) 277:3079-3084.
  • COLE AM, HONG T, BOO LM et al.: Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc. Natl. Acad. Sci. USA (2002) 99:1813-1818.
  • MUNK C, WEI G, YANG OO et al.: The θ-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res. Hum. Retroviruses (2003) 19:875-881.
  • SELSTED ME: θ-defensins: cyclic antimicrobial peptides produced by binary ligation of truncated α-defensins. Curr. Protein Pept. Sci. (2004) 5:365-371.
  • SELSTED ME, TANG YQ, MORRIS WL et al.: Purification, primary structures, and antibacterial activities of β-defensins, a new family of antimicrobial peptides from bovine neutrophils. J. Biol. Chem. (1993) 268:6641-6648.
  • WILDE CG, GRIFFITH JE, MARRA MN, SNABLE JL, SCOTT RW: Purification and characterization of human neutrophil peptide 4, a novel member of the defensin family. J. Biol. Chem. (1989) 264:11200-11203.
  • ZHAO C, WANG I, LEHRER RI: Widespread expression of β-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett. (1996) 396:319-322.
  • SCHALLER-BALS S, SCHULZE A, BALS R: Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am. J. Respir. Crit. Care Med. (2002) 165:992-995.
  • HARDER J, MEYER-HOFFERT U, TERAN LM et al.: Mucoid Pseudomonas aeruginosa, TNF-α, and IL-1β but not IL-6, induce human β-defensin-2 in respiratory epithelia. Am. J. Respir. Cell Mol. Biol. (2000) 22:714-721.
  • DUITS LA, NIBBERING PH, VAN SE et al.: Rhinovirus increases human β-defensin-2 and -3 mRNA expression in cultured bronchial epithelial cells. FEMS Immunol. Med. Microbiol. (2003) 38:59-64.
  • TSUTSUMI-ISHII Y, NAGAOKA I: NF-κB-mediated transcriptional regulation of human β-defensin-2 gene following lipopolysaccharide stimulation. J. Leukoc. Biol. (2002) 71:154-162.
  • KRISANAPRAKORNKIT S, KIMBALL JR, DALE BA: Regulation of human β-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways but not the NF-κB transcription factor family. J. Immunol. (2002) 168:316-324.
  • MOON SK, LEE HY, LI JD et al.: Activation of a Src-dependent Raf-MEK1/2-ERK signalling pathway is required for IL-1α-induced upregulation of β-defensin 2 in human middle ear epithelial cells. Biochim. Biophys. Acta (2002) 1590:41-51.
  • WANG X, ZHANG Z, LOUBOUTIN JP, MOSER C, WEINER DJ, WILSON JM: Airway epithelia regulate expression of human β-defensin 2 through Toll-like receptor 2. FASEB J. (2003) 17:1727-1729.
  • LU Z, KIM KA, SUICO MA, SHUTO T, LI JD, KAI H: MEF upregulates human β-defensin 2 expression in epithelial cells. FEBS Lett. (2004) 561:117-121.
  • TOMITA T, NAGASE T, OHGA E, YAMAGUCHI Y, YOSHIZUMI M, OUCHI Y: Molecular mechanisms underlying human β-defensin-2 gene expression in a human airway cell line (LC2/ad). Respirology (2002) 7:305-310.
  • HERTZ CJ, WU Q, PORTER EM et al.: Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human β defensin-2. J. Immunol. (2003) 171:6820-6826.
  • BIRCHLER T, SEIBL R, BUCHNER K et al.: Human Toll-like receptor 2 mediates induction of the antimicrobial peptide human β-defensin 2 in response to bacterial lipoprotein. Eur. J. Immunol. (2001) 31:3131-3137.
  • BECKER MN, DIAMOND G, VERGHESE MW, RANDELL SH: CD14-dependent lipopolysaccharide-induced β-defensin-2 expression in human tracheobronchial epithelium. J. Biol. Chem. (2000) 275:29731-29736.
  • TSUTSUMI-ISHII Y, NAGAOKA I: Modulation of human β-defensin-2 transcription in pulmonary epithelial cells by lipopolysaccharide-stimulated mononuclear phagocytes via pro-inflammatory cytokine production. J. Immunol. (2003) 170:4226-4236.
  • GRIFFIN S, TAGGART CC, GREENE CM, O'NEILL S, MCELVANEY NG: Neutrophil elastase upregulates human β-defensin-2 expression in human bronchial epithelial cells. FEBS Lett. (2003) 546:233-236.
  • AGERBERTH B, GUNNE H, ODEBERG J, KOGNER P, BOMAN HG, GUDMUNDSSON GH: FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc. Natl. Acad. Sci. USA (1995) 92:195-199.
  • LIU PT, STENGER S, LI H et al.: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science (2006) 311:1770-1773.
  • GOMBART AF, BORREGAARD N, KOEFFLER HP: Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly upregulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. (2005) 19:1067-1077.
  • ZUYDERDUYN S, NINABER DK, HIEMSTRA PS, RABE KF: The antimicrobial peptide LL-37 enhances IL-8 release by human airway smooth muscle cells. J. Allergy Clin. Immunol. (2006) 117:1328-1335.
  • CHEN CI, SCHALLER-BALS S, PAUL KP, WAHN U, BALS R: β-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J. Cyst. Fibros. (2004) 3:45-50.
  • BEISSWENGER C, KANDLER K, HESS C et al.: Allergic airway inflammation inhibits pulmonary antibacterial host defense. J. Immunol. (2006) 177:1833-1837.
  • TAGGART CC, GREENE CM, SMITH SG et al.: Inactivation of human β-defensins 2 and 3 by elastolytic cathepsins. J. Immunol. (2003) 171:931-937.
  • SCHMIDTCHEN A, FRICK IM, ANDERSSON E, TAPPER H, BJORCK L: Proteases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol. Microbiol. (2002) 46:157-168.
  • WEINER DJ, BUCKI R, JANMEY PA: The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am. J. Respir. Cell Mol. Biol. (2003) 28:738-745.
  • FELGENTREFF K, BEISSWENGER C, GRIESE M, GULDER T, BRINGMANN G, BALS R: The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides (2006) 27:3100-3106.
  • HERASIMENKA Y, BENINCASA M, MATTIUZZO M, CESCUTTI P, GENNARO R, RIZZO R: Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens. Peptides (2005) 26:1127-1132.
  • GANZ T, SELSTED ME, SZKLAREK D et al.: Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest. (1985) 76:1427-1435.
  • OUELLETTE AJ, SELSTED ME: Paneth cell defensins: endogenous peptide components of intestinal host defense. FASEB J. (1996) 10:1280-1289.
  • LEHRER RI, BARTON A, DAHER KA, HARWIG SS, GANZ T, SELSTED ME: Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J. Clin. Invest. (1989) 84:553-561.
  • WILSON CL, OUELLETTE AJ, SATCHELL DP et al.: Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense. Science (1999) 286:113-117.
  • MOSER C, WEINER DJ, LYSENKO E, BALS R, WEISER JN, WILSON JM: β-Defensin 1 contributes to pulmonary innate immunity in mice. Infect. Immun. (2002) 70:3068-3072.
  • MORRISON G, KILANOWSKI F, DAVIDSON D, DORIN J: Characterization of the mouse β defensin 1, Defb1, mutant mouse model. Infect. Immun. (2002) 70:3053-3060.
  • NIZET V, OHTAKE T, LAUTH X et al.: Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature (2001) 414:454-457.
  • CHROMEK M, SLAMOVA Z, BERGMAN P et al.: The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. (2006) 12:636-641.
  • BALS R, WEINER DJ, MEEGALLA RL, WILSON JM: Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J. Clin. Invest. (1999) 103:1113-1117.
  • SALZMAN NH, GHOSH D, HUTTNER KM, PATERSON Y, BEVINS CL: Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature (2003) 422:522-526.
  • KLOTMAN ME, CHANG TL: Defensins in innate antiviral immunity. Nat. Rev. Immunol. (2006) 6:447-456.
  • QUINONES-MATEU ME, LEDERMAN MM, FENG Z et al.: Human epithelial β-defensins 2 and 3 inhibit HIV-1 replication. AIDS (2003) 17:F39-F48.
  • PROUD D, SANDERS SP, WIEHLER S: Human rhinovirus infection induces airway epithelial cell production of human β-defensin 2 both in vitro and in vivo. J. Immunol. (2004) 172:4637-4645.
  • MACKEWICZ CE, YUAN J, TRAN P et al.: α-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS (2003) 17:F23-F32.
  • CHANG TL, VARGAS JJ, DELPORTILLO A, KLOTMAN ME: Dual role of α-defensin-1 in anti-HIV-1 innate immunity. J. Clin. Invest. (2005).
  • CHANG TL, FRANCOIS F, MOSOIAN A, KLOTMAN ME: CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from β-defensin-1 HIV inhibition. J. Virol. (2003) 77:6777-6784.
  • WANG W, OWEN SM, RUDOLPH DL et al.: Activity of α- and θ-defensins against primary isolates of HIV-1. J. Immunol. (2004) 173:515-520.
  • LYSENKO ES, GOULD J, BALS R, WILSON JM, WEISER JN: Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect. Immun. (2000) 68:1664-1671.
  • ERNST RK, YI EC, GUO L et al.: Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science (1999) 286:1561-1565.
  • SMITH JJ, TRAVIS SM, GREENBERG EP, WELSH MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell (1996) 85:229-236.
  • MARTIN RJ, KRAFT M, CHU HW, BERNS EA, CASSELL GH: A link between chronic asthma and chronic infection. J. Allergy Clin. Immunol. (2001) 107:595-601.
  • MURPHY TF: The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease. Curr. Opin. Infect. Dis. (2006) 19:225-230.
  • CHILVERS MA, O'CALLAGHAN C: Local mucociliary defence mechanisms. Paediatr. Respir. Rev. (2000) 1:27-34.
  • SOONG LB, GANZ T, ELLISON A, CAUGHEY GH: Purification and characterization of defensins from cystic fibrosis sputum. Inflamm. Res. (1997) 46:98-102.
  • PANYUTICH AV, PANYUTICH EA, KRAPIVIN VA, BATUREVICH EA, GANZ T: Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J. Lab. Clin. Med. (1993) 122:202-207.
  • VAN WS, MANNESSE-LAZEROMS SP, DIJKMAN JH, HIEMSTRA PS: Effect of neutrophil serine proteases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J. Leukoc. Biol. (1997) 62:217-226.
  • AARBIOU J, TJABRINGA GS, VERHOOSEL RM et al.: Mechanisms of cell death induced by the neutrophil antimicrobial peptides α-defensins and LL-37. Inflamm. Res. (2006) 55:119-127.
  • VAN WS, MANNESSE-LAZEROMS SP, VAN STERKENBURG MA et al.: Effect of defensins on interleukin-8 synthesis in airway epithelial cells. Am. J. Physiol. (1997) 272:L888-L896.
  • VAN WS, MANNESSE-LAZEROMS SP, VAN STERKENBURG MA, HIEMSTRA PS: Neutrophil defensins stimulate the release of cytokines by airway epithelial cells: modulation by dexamethasone. Inflamm. Res. (2002) 51:8-15.
  • ASHITANI J, MUKAE H, NAKAZATO M et al.: Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis. Eur. Respir. J. (1998) 11:104-111.
  • PANYUTICH AV, HIEMSTRA PS, VAN WS, GANZ T: Human neutrophil defensin and serpins form complexes and inactivate each other. Am. J. Respir. Cell Mol. Biol. (1995) 12:351-357.
  • ZHANG H, PORRO G, ORZECH N, MULLEN B, LIU M, SLUTSKY AS: Neutrophil defensins mediate acute inflammatory response and lung dysfunction in dose-related fashion. Am. J. Physiol. Lung. Cell Mol. Physiol. (2001) 280:L947-L954.
  • OPPENHEIM JJ, YANG D: Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. (2005) 17:359-365.
  • HIRATA M, ZHONG J, WRIGHT SC, LARRICK JW: Structure and functions of endotoxin-binding peptides derived from CAP18. Prog. Clin. Biol. Res. (1995) 392:317-326.
  • BRACKETT DJ, LERNER MR, LACQUEMENT MA, HE R, PEREIRA HA: A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats. Infect. Immun. (1997) 65:2803-2811.
  • LILLARD JW Jr, BOYAKA PN, CHERTOV O, OPPENHEIM JJ, MCGHEE JR: Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc. Natl. Acad. Sci. USA (1999) 96:651-656.
  • YANG D, BIRAGYN A, HOOVER DM, LUBKOWSKI J, OPPENHEIM JJ: Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. (2004) 22:181-215.
  • CHERTOV O, MICHIEL DF, XU L et al.: Identification of defensin-1, defensin-2, and CAP37/azurocidin as T cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J. Biol. Chem. (1996) 271:2935-2940.
  • YANG D, CHEN Q, CHERTOV O, OPPENHEIM JJ: Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. (2000) 68:9-14.
  • BIRAGYN A, SURENHU M, YANG D et al.: Mediators of innate immunity that target immature but not mature, dendritic cells induce antitumour immunity when genetically fused with nonimmunogenic tumour antigens. J. Immunol. (2001) 167:6644-6653.
  • YANG D, CHERTOV O, BYKOVSKAIA SN et al.: β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 286:525-528.
  • NIYONSABA F, IWABUCHI K, MATSUDA H, OGAWA H, NAGAOKA I: Epithelial cell-derived human β-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway. Int. Immunol. (2002) 14:421-426.
  • DE Y, CHEN Q, SCHMIDT AP et al.: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. (2000) 192:1069-1074.
  • NAGAOKA I, TAMURA H, HIRATA M: An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7. J. Immunol. (2006) 176:3044-3052.
  • NIYONSABA F, SOMEYA A, HIRATA M, OGAWA H, NAGAOKA I: Evaluation of the effects of peptide antibiotics human β-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur. J. Immunol. (2001) 31:1066-1075.
  • BOWDISH DM, DAVIDSON DJ, SPEERT DP, HANCOCK RE: The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. (2004) 172:3758-3765.
  • ELSSNER A, DUNCAN M, GAVRILIN M, WEWERS MD: A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 β processing and release. J. Immunol. (2004) 172:4987-4994.
  • DAVIDSON DJ, CURRIE AJ, REID GS et al.: The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. (2004) 172:1146-1156.
  • DI NA, BRAFF MH, TAYLOR KR et al.: Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J. Immunol. (2007) 178:1829-1834.
  • KANDLER K, SHAYKHIEV R, KLEEMANN P et al.: The antimicrobial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. Int. Immunol. (2006) 18:1729-1736.
  • AARBIOU J, ERTMANN M, VAN WS et al.: Human neutrophil defensins induce lung epithelial cell proliferation in vitro. J. Leukoc. Biol. (2002) 72:167-174.
  • AARBIOU J, VERHOOSEL RM, VAN WS et al.: Neutrophil defensins enhance lung epithelial wound closure and mucin gene expression in vitro. Am. J. Respir. Cell Mol. Biol. (2004) 30:193-201.
  • TJABRINGA GS, AARBIOU J, NINABER DK et al.: The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. (2003) 171:6690-6696.
  • HEILBORN JD, NILSSON MF, KRATZ G et al.: The cathelicidin antimicrobial peptide LL-37 is involved in reepithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. (2003) 120:379-389.
  • SHAYKHIEV R, BEISSWENGER C, KANDLER K et al.: Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 289:L842-L848.
  • KOCZULLA R, VON DG, KUPATT C et al.: An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. (2003) 111:1665-1672.
  • LI J, POST M, VOLK R et al.: PR39, a peptide regulator of angiogenesis. Nat. Med. (2000) 6:49-55.
  • GALLO RL, ONO M, POVSIC T et al.: Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc. Natl. Acad. Sci. USA (1994) 91:11035-11039.
  • ZEIDLER C, WELTE K: Kostmann syndrome and severe congenital neutropenia. Semin. Hematol. (2002) 39:82-88.
  • PUTSEP K, CARLSSON G, BOMAN HG, ANDERSSON M: Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet (2002) 360:1144-1149.
  • ONG PY, OHTAKE T, BRANDT C et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. (2002) 347:1151-1160.
  • NOMURA I, GOLEVA E, HOWELL MD et al.: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. (2003) 171:3262-3269.
  • ISLAM D, BANDHOLTZ L, NILSSON J et al.: Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. Nat. Med. (2001) 7:180-185.
  • FELLERMANN K, WEHKAMP J, HERRLINGER KR, STANGE EF: Crohn's disease: a defensin deficiency syndrome? Eur. J. Gastroenterol. Hepatol. (2003) 15:627-634.
  • LAAN M, BOZINOVSKI S, ANDERSON GP: Cigarette smoke inhibits lipopolysaccharide-induced production of inflammatory cytokines by suppressing the activation of activator protein-1 in bronchial epithelial cells. J. Immunol. (2004) 173:4164-4170.
  • CIRCO R, SKERLAVAJ B, GENNARO R, AMOROSO A, ZANETTI M: Structural and functional characterization of hBD-1(Ser35), a peptide deduced from a DEFB1 polymorphism. Biochem. Biophys. Res. Commun. (2002) 293:586-592.
  • MATSUSHITA I, HASEGAWA K, NAKATA K, YASUDA K, TOKUNAGA K, KEICHO N: Genetic variants of human β-defensin-1 and chronic obstructive pulmonary disease. Biochem. Biophys. Res. Commun. (2002) 291:17-22.
  • VATTA S, BONIOTTO M, BEVILACQUA E et al.: Human β defensin 1 gene: six new variants. Hum. Mutat. (2000) 15:582-583.
  • DORK T, STUHRMANN M: Polymorphisms of the human β-defensin-1 gene. Mol. Cell Probes. (1998) 12:171-173.
  • JUREVIC RJ, BAI M, CHADWICK RB, WHITE TC, DALE BA: Single-nucleotide polymorphisms (SNPs) in human β-defensin 1: high-throughput SNP assays and association with Candida carriage in Type I diabetics and nondiabetic controls. J. Clin. Microbiol. (2003) 41:90-96.
  • HOLLOX EJ, ARMOUR JA, BARBER JC: Extensive normal copy number variation of a β-defensin antimicrobial-gene cluster. Am. J. Hum. Genet. (2003) 73:591-600.
  • HIRATSUKA T, NAKAZATO M, DATE Y et al.: Identification of human β-defensin-2 in respiratory tract and plasma and its increase in bacterial pneumonia. Biochem. Biophys. Res. Commun. (1998) 249:943-947.
  • ASHITANI J, MUKAE H, NAKAZATO M et al.: Elevated pleural fluid levels of defensins in patients with empyema. Chest (1998) 113:788-794.
  • ASHITANI J, MUKAE H, HIRATSUKA T, NAKAZATO M, KUMAMOTO K, MATSUKURA S: Elevated levels of α-defensins in plasma and BAL fluid of patients with active pulmonary tuberculosis. Chest (2002) 121:519-526.
  • ASHITANI J, MUKAE H, HIRATSUKA T, NAKAZATO M, KUMAMOTO K, MATSUKURA S: Plasma and BAL fluid concentrations of antimicrobial peptides in patients with Mycobacterium avium-intracellulare infection. Chest (2001) 119:1131-1137.
  • RIVAS-SANTIAGO B, SADA E, TSUTSUMI V, GUILAR-LEON D, CONTRERAS JL, HERNANDEZ-PANDO R: β-Defensin gene expression during the course of experimental tuberculosis infection. J. Infect. Dis. (2006) 194:697-701.
  • WEBER G, HEILBORN JD, CHAMORRO JIMENEZ CI, HAMMARSJO A, TORMA H, STAHLE M: Vitamin D induces the antimicrobial protein hCAP18 in human skin. J. Invest. Dermatol. (2005) 124:1080-1082.
  • ZASLOFF M: Fighting infections with vitamin D. Nat. Med. (2006) 12:388-390.
  • BALS R, WEINER DJ, MEEGALLA RL, ACCURSO F, WILSON JM: Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am. J. Respir. Cell Mol. Biol. (2001) 25:21-25.
  • DAULETBAEV N, GROPP R, FRYE M, LOITSCH S, WAGNER TO, BARGON J: Expression of human β defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult cystic fibrosis patients, healthy individuals, and individuals with acute cold. Respiration (2002) 69:46-51.
  • YANAGIHARA K, KADOTO J, KOHNO S: Diffuse panbronchiolitis-pathophysiology and treatment mechanisms. Int. J. Antimicrob. Agents (2001) 18(Suppl. 1):S83-S87.
  • ASHITANI J, MUKAE H, IHIBOSHI H et al.: Defensin in plasma and in bronchoalveolar lavage fluid from patients with acute respiratory distress syndrome. Nihon Kyobu Shikkan Gakkai Zasshi (1996) 34:1349-1353.
  • HIRATSUKA T, MUKAE H, IIBOSHI H et al.: Increased concentrations of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax (2003) 58:425-430.
  • HERSH CP, DEMEO DL, RABY BA et al.: Genetic linkage and association analysis of COPD-related traits on chromosome 8p. COPD (2006) 3:189-194.
  • HIRATA M, SHIMOMURA Y, YOSHIDA M, WRIGHT SC, LARRICK JW: Endotoxin-binding synthetic peptides with endotoxin-neutralizing, antibacterial and anticoagulant activities. Prog. Clin. Biol. Res. (1994) 388:147-159.
  • CIRIONI O, GIACOMETTI A, GHISELLI R et al.: LL-37 protects rats against lethal sepsis caused by Gram-negative bacteria. Antimicrob. Agents Chemother. (2006) 50:1672-1679.
  • MUKAE H, IIBOSHI H, NAKAZATO M et al.: Raised plasma concentrations of α-defensins in patients with idiopathic pulmonary fibrosis. Thorax (2002) 57:623-628.
  • ASHITANI J, MATSUMOTO N, NAKAZATO M: Elevated levels of antimicrobial peptides in bronchoalveolar lavage fluid in patients with chronic eosinophilic pneumonia. Respiration (2007) 74:69-75.
  • PRESNEILL JJ, NAKATA K, INOUE Y, SEYMOUR JF: Pulmonary alveolar proteinosis. Clin. Chest Med. (2004) 25:593-613.
  • MUKAE H, ISHIMOTO H, YANAGI S et al.: Elevated BALF concentrations of α- and β-defensins in patients with pulmonary alveolar proteinosis. Respir. Med. (2007) 101:715-721.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.